Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Sanofi strikes $1.5B global licensing deal for Sino Biopharm’s first-in-class JAK/ROCK asset

Sanofi strikes $1.5B global licensing deal for Sino Biopharm’s first-in-class JAK/ROCK asset

  • March 4, 2026

Sanofi is betting $1.53 billion on a novel drug from Sino Biopharmaceutical, securing global rights to a first-in-class JAK/ROCK inhibitor that could play a double role in the French pharma’s hematology and immunology pipeline.

Leave A Comment

Fields (*) Mark are Required